NYSE: NVS
Positive Data on Novartis' Jakavi - Analyst Blog
Positive Data on Novartis' Jakavi - Analyst BlogThis Blockbuster Biologic May Face a Steep Cliff
Neulasta generated sales north of $4 billion for Amgen in 2012, but generic competition is brewing on two continents.3 Humongous Health-Care Stocks This Week
These stocks skyrocketed this week. But will gravity soon kick in?Encouraging Data on Novartis' Gilenya - Analyst Blog
Encouraging Data on Novartis' Gilenya - Analyst Blog1 Thing You Always Wanted to Know About Drugs (but Were Afraid to Ask)
Two fascinating approaches pharmaceutical companies use to discover new drugs.Big Pharma's Biggest Opportunity
Are emerging markets the magic cure for patent loss-related sales around the pharmaceutical industry?